Viriom: Viriom and Chromis publish results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021

Press Release: Viriom : Viriom Announces Initiation of Phase 2 Study Investigating Efficacy of Intramuscular Long-Acting Injectable Nanoformulation of VM1500A in HIV-Infected Patients

Viriom: Viriom Initiates Phase 2 Clinical Study of Elsulfavirine for Treatment of COVID-19

Press Release: Viriom : Viriom donates Elpida to Chinese and Russian governments for experimental use against COVID-19; also working with global health authorities to determine the efficacy and safety of Elpida and its other clinical candidates AV5080, AV5124 and AV5126 against COVID-19

Press Release: Viriom : Viriom to present results of Phase I study of the long acting injectable formulation of novel NNRTi for treatment of HIV-1 infection at CROI 2020

Press Release: Viriom : Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation

Viriom: Viriom Wins Grant Award to Establish Affiliate in Mainland China

Viriom: Viriom announces NIH/NIAID and Division of AIDS Collaboration with the Long-Acting/Extended Release Antiviral Resource Program

Press Release: Viriom : Viriom Signed Licensing Agreement for Indonesia with P.T. Lloyd Pharma

Press Release: Viriom : Viriom Files for Market Authorization in China